Combining miRNA and mRNA Expression Profiles in Wilms Tumor Subtypes-Reference-Cited by-同舟云学术

Combining miRNA and mRNA Expression Profiles in Wilms Tumor Subtypes

Published:2016-03-30 Issue:4 Volume:17 Page:475
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Ludwig Nicole,Werner Tamara,Backes Christina,Trampert Patrick,Gessler Manfred,Keller Andreas,Lenhof Hans-Peter,Graf Norbert,Meese Eckart

Funder

Deutsche Forschungsgemeinschaft

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/17/4/475/pdf

Reference61 articles.

1. Wilms Tumor

2. Update on Relapses in Unilateral Nephroblastoma Registered in 3 Consecutive SIOP/GPOH Studies - A Report from the GPOH-Nephroblastoma Study Group

3. Role of MRI in the management of patients with nephroblastoma

4. Kindliche Nierentumoren — Relevanz der Bildgebung

5. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural products and long noncoding RNA signatures in gallbladder cancer: a review focuses on pathogenesis, diagnosis, and drug resistance;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-19

2. miRNAs Role in Wilms tumor pathogenesis: Signaling pathways interplay;Pathology - Research and Practice;2024-04

3. Nephroblastoma-specific dysregulated gene SNHG15 with prognostic significance: scRNA-Seq with bulk RNA-Seq data and experimental validation;Discover Oncology;2024-03-25

4. Multidimensional Transcriptomics Unveils RNF34 as a Prognostic Biomarker and Potential Indicator of Chemotherapy Sensitivity in Wilms’ Tumour;Molecular Biotechnology;2024-01-09

5. Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer;Frontiers in Oncology;2023-11-07